Welcome to our dedicated page for Sol Gel Tech news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Tech stock.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is a dermatology company whose news flow centers on clinical trial progress, regulatory milestones, licensing transactions and financial updates related to its topical drug products and pipeline. The company developed TWYNEO, a fixed-dose combination cream for acne vulgaris, and EPSOLAY, a benzoyl peroxide cream for inflammatory lesions of rosacea, and continues to report on ex-U.S. approvals and commercialization agreements for these products.
Recent Sol-Gel news highlights include updates on its pivotal Phase 3 clinical trial of SGT-610 (patidegib gel 2%) for Gorlin syndrome, including completion of patient enrollment and expectations for future top-line results. The company also issues releases on exploratory work to extend SGT-610 into high-frequency basal cell carcinoma and on compassionate-use cases in patients with PTCH1-mutated lesions. For SGT-210, a topical erlotinib candidate for Darier disease and other rare hyperkeratinization disorders, Sol-Gel has reported on Phase 1b proof-of-concept data, trial design decisions and plans for feasibility studies in additional indications.
Investors following SLGL news will also find announcements on Health Canada’s approval of EPSOLAY, new license agreements with partners such as Searchlight Pharma, Viatris and regional distributors, and a product purchase agreement with a subsidiary of Mayne Pharma for U.S. rights to EPSOLAY and TWYNEO. Periodic financial results releases provide detail on revenue from licensing and royalties, research and development spending on SGT-610 and SGT-210, cash runway expectations and capital market developments such as the company’s reverse share split and Nasdaq listing status.
This news page aggregates these company-issued updates and related coverage, making it easier to track Sol-Gel’s clinical, regulatory and commercial milestones over time for its dermatology portfolio and rare disease pipeline.
Sol-Gel Technologies (NASDAQ: SLGL) reported Q3 2022 financial results with revenue of $0.3 million, a significant decline from $8.8 million in Q3 2021. The decreased revenue is attributed to lower sales from EPSOLAY and TWYNEO, despite improvements in prescriber adoption. Research and development expenses dropped to $2.0 million from $6.0 million year-over-year, aiding in cash management. The company reported a loss of $3.4 million, down from a profit of $1.3 million in the previous year. However, Sol-Gel's cash runway is projected to last through Q1 2024, supported by ongoing partnerships.
Sol-Gel Technologies (NASDAQ: SLGL) has appointed Michael Glezin as Vice President of Business Development. Glezin, who has over a decade of experience in in-licensing and out-licensing within multiple territories, will focus on securing new business opportunities and commercial partnerships outside the U.S. His prior experience includes a senior role at Dexcel Pharma. CEO Alon Seri-Levy emphasized that Glezin's expertise will enhance Sol-Gel's growth potential and revenue streams from its microencapsulation technology and approved drugs, TWYNEO and EPSOLAY, which are exclusively licensed to Galderma.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) reported strong prescription volumes for its products EPSOLAY and TWYNEO, indicating a favorable launch trajectory. The company received a $3.5 million milestone payment from Galderma for FDA approval of EPSOLAY, boosting revenues to $3.5 million for Q2 2022, compared to $0.9 million in the previous year. R&D expenses decreased to $2.4 million, contributing to a reduced net loss of $0.1 million compared to $8.0 million in Q2 2021. With $36.6 million in cash and securities, Sol-Gel can fund its operations through the end of 2023.
Sol-Gel Technologies (NASDAQ: SLGL) has announced that CEO Alon Seri-Levy will present a corporate update at the 2022 Jefferies Global Healthcare Conference from June 8-10, 2022, in New York, NY. The presentation will occur on June 8 at 8:30 am ET in Track 9, with additional 1:1 meetings available. Sol-Gel is focused on developing topical drug products for skin diseases, including TWYNEO® and EPSOLAY, both licensed to Galderma for U.S. commercialization. The company is also advancing early-stage candidates SGT-210, SGT-310, and SGT-510 for other dermatologic indications.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology-focused company, announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The event will feature an on-demand presentation starting May 24 at 7:00 AM EDT, along with one-on-one meetings. Sol-Gel specializes in developing topical drugs, including TWYNEO® for acne treatment and EPSOLAY for rosacea, both licensed to Galderma. The company is also advancing early-stage drug candidates for various dermatological diseases.
Sol-Gel Technologies (SLGL) announced FDA approval for EPSOLAY®, a benzoyl peroxide cream for treating inflammatory lesions of rosacea, marking their second product launch within a year. Partner Galderma is set to launch EPSOLAY this quarter, following the successful U.S. launch of TWYNEO in April, targeting acne vulgaris. Despite nominal revenue of $0 for Q1 2022, and a reported loss of $5.6 million, the company expects its cash runway to extend through the end of 2023, thanks to partnerships that are poised to enhance product availability in dermatological treatments.
Sol-Gel Technologies (NASDAQ: SLGL) announced FDA approval for EPSOLAY, a benzoyl peroxide cream (5%) for treating rosacea in adults. The exclusive commercialization rights have been granted to Galderma. Clinical trials demonstrated a nearly 70% reduction in inflammatory lesions after 12 weeks, with 50% of patients achieving clear or almost clear skin. EPSOLAY's microencapsulation technology allows for sustained drug release, enhancing efficacy and safety. The product is patent-protected until 2040, indicating strong market potential for the 16 million Americans affected by rosacea.
Sol-Gel Technologies (NASDAQ: SLGL) announced the U.S. launch of TWYNEO, the first FDA-approved topical cream combining tretinoin and benzoyl peroxide for acne treatment. Launched by partner Galderma at the American Academy of Dermatology conference on March 25-29, 2022, TWYNEO is available by prescription across major U.S. pharmacy chains. The product's microencapsulation technology allows for controlled release of its active ingredients, addressing acne in adults and pediatric patients aged nine and older.
Sol-Gel Technologies (SLGL) reported 2021 revenue of $31.3 million, a combination of $7.5 million in licensing and $23.8 million in collaboration revenue. The company achieved net income of $3.2 million or $0.14 earnings per share, compared to a loss in 2020. Following an agreement with Padagis, Sol-Gel will receive $21.5 million over 24 months, allowing it to focus on high-value drug development. The launch of TWYNEO® is set for Spring 2022, enhancing its product portfolio alongside the anticipated EPSOLAY approval.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) announces the commercial launch of TWYNEO in Spring 2022, a groundbreaking 2-in-1 topical cream combining tretinoin and benzoyl peroxide, specifically designed to treat moderate-to-severe acne.
Galderma, Sol-Gel’s U.S. commercialization partner, will promote TWYNEO at the AAD Annual Meeting from March 25-29, 2022, in Boston. TWYNEO utilizes patented microencapsulation technology for effective and timely delivery. CEO Alon Seri-Levy highlights the significance of this product for both patients and investors.